WO2021203606A1 - Preparation method for compound amino acid injection for livestock - Google Patents

Preparation method for compound amino acid injection for livestock Download PDF

Info

Publication number
WO2021203606A1
WO2021203606A1 PCT/CN2020/109808 CN2020109808W WO2021203606A1 WO 2021203606 A1 WO2021203606 A1 WO 2021203606A1 CN 2020109808 W CN2020109808 W CN 2020109808W WO 2021203606 A1 WO2021203606 A1 WO 2021203606A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
compound amino
acid injection
solution
protection
Prior art date
Application number
PCT/CN2020/109808
Other languages
French (fr)
Chinese (zh)
Inventor
李凤英
陈淑芳
赵素娟
郭艳玉
李艳
王伟光
邢江盼
Original Assignee
河北科星药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 河北科星药业有限公司 filed Critical 河北科星药业有限公司
Publication of WO2021203606A1 publication Critical patent/WO2021203606A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4172Imidazole-alkanecarboxylic acids, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals

Definitions

  • the invention belongs to the technical field of animal husbandry and veterinary medicine, and relates to a preparation method of animal injection, in particular to a preparation method of animal compound amino acid injection.
  • the supplementary liquid used to enhance the physical fitness of animals mainly uses glucose injection, sodium chloride injection and glucose sodium chloride injection. These three injections mainly play the role of supplementing water and energy, and regulating the balance of body electrolytes, but they cannot improve the nutritional status of the animal body and supplement the amino acids required by the animal body, and thus cannot effectively regulate the animal's feed intake, especially for the weak During the onset of the disease, the animals need to supplement amino acids to improve their nutrition to promote the recovery of the animals.
  • the Chinese invention patent with the patent number 201210000911.5 discloses a technical solution of compound amino acid injection.
  • the technical solution is mainly used for the treatment of animal diseases and the restoration of the body during the recovery period after the disease, supplementing the essential and non-essential amino acids required by the animal body.
  • the existing animal compound amino acid injections have poor amino acid stability, which is not conducive to the storage of animal compound amino acid injections.
  • the purpose of the present invention is to provide a method for preparing a compound amino acid injection for livestock, so as to solve the problem of poor stability of each amino acid in the injection for livestock.
  • a preparation method of compound amino acid injection for animal use includes the following steps in sequence:
  • group B amino acids are calculated in parts by weight, including: 1.00 to 4.00 parts of arginine, 0.80 to 2.54 parts of histidine, 1.50 to 2.88 parts of leucine, 0.50 to 2.00 parts of isoleucine, and 1.00 to 4.50 parts Lysine, 1.00 to 2.96 parts of phenylalanine, 0.80 to 2.11 parts of threonine, 0.50 to 2.50 parts of valine, 0.50 to 2.10 parts of methionine, 1.00 to 3.45 parts of glycine, 0.80 to 3.00 parts of alanine Acid, 0.50 to 2.40 parts of proline, 0.25 to 1.50 parts of serine, 0.50 to 1.25 parts of aspartic acid, 0.80 to 2.25 parts of glutamic acid;
  • amino acids of group D are calculated in parts by weight, including: 0.20 to 0.70 parts of tryptophan, 0.05 to 0.15 parts of tyrosine, and 0.20 to 1.00 parts of cysteine hydrochloride;
  • the ratio of parts by weight to parts by volume is kg:L;
  • active carbon is added to the intermediate solution F, decolorized at 20-35° C., and filtered to prepare the compound amino acid injection for livestock.
  • the prepared animal compound amino acid injection is sterilized.
  • the animal compound amino acid injection is filled.
  • the weight-volume ratio of the activated carbon to the intermediate solution F is 0.5-1 kg:1000L.
  • the decolorization temperature is 20 to 35° C. and the time is 30 to 40 min.
  • filtration includes coarse filtration and fine filtration in sequence
  • Fine filtration is a microporous filter element filtration
  • the pore size of the microporous filter element is 0.45 ⁇ m, 0.22 ⁇ m or 0.20 ⁇ m.
  • the residual oxygen content in the container during the filling process is less than or equal to 3%.
  • the sterilization temperature is 110-121°C, and the time is 15-40 min.
  • the present invention improves the content and stability of amino acids in compound amino acid injections for livestock by changing the process parameters, and the details are as follows:
  • the present invention adopts stepwise feeding to prepare animal amino acid injection, and simultaneously adds tryptophan, tyrosine, and cysteine hydrochloride at 60-70°C under the protection of CO 2 to reduce the feeding temperature of tyrosine , While ensuring that the solubility of tyrosine does not decrease, it effectively prevents the oxidation of tryptophan and tyrosine, and improves the stability of compound amino acid injections for livestock;
  • cysteine hydrochloride together with tyrosine and tryptophan can protect tryptophan and tyrosine from being oxidized, and effectively improve the stability of tryptophan and tyrosine, and the level of tryptophan is 60%.
  • the solubility reaches the best at ⁇ 70°C, which not only increases the content of tryptophan and tyrosine in animal amino acid injection, but also improves the stability of tyrosine and tryptophan.
  • the dissolution time is shortened, thereby reducing the preparation time and improving the production efficiency.
  • the animal compound amino acid injection prepared by the invention is suitable for body repair during the treatment of animal diseases and during the recovery period after the disease.
  • This embodiment is a preparation method of compound amino acid injection for animals. Taking 1m3 compound injection for animals as an example, the specific preparation method includes the following steps in sequence:
  • sodium bisulfite has the effect of preventing the oxidation of tryptophan and tyrosine. Therefore, adding sodium bisulfite before adding each amino acid has a better antioxidant effect.
  • Disodium ethylenediaminetetraacetate can be combined with the raw materials. The introduced metal ions perform chelation to prevent the metal ions from catalyzing the oxidation of amino acids. Therefore, in this embodiment, the sodium bisulfite and disodium edetate are dissolved before adding each amino acid.
  • Tryptophan in compound amino acid injection is a component that is easy to oxidize and decompose.
  • Other amino acids may also be oxidized and decomposed.
  • the stability of amino acids is greatly affected by the oxygen content in the liquid. The higher the oxygen content, the more the amino acid is oxidized and decomposed, the worse the stability, and the darker the color of the drug solution. Therefore, the inert gas protection is used at the beginning of the preparation, which can effectively reduce the oxygen content in the drug solution, so that the amino acid can be sterilized and sterilized later. More stable during storage.
  • the dissolution time of amino acids decreases with the increase of temperature.
  • the dissolution time is the shortest, and when the temperature is higher than 70°C, most of the amino acid content changes no longer change significantly.
  • each amino acid is added step by step, adding arginine, histidine, leucine, isoleucine, lysine, phenylalanine, threonine, valine, Methionine, glycine, alanine, proline, serine, aspartic acid, and glutamic acid are dissolved at 70 ⁇ 100°C, tryptophan and tyrosine are dissolved at 60 ⁇ 70°C, At the same time, it dissolves cysteine hydrochloride to reduce the oxidation of tryptophan and tyrosine in the process of dissolving.
  • ⁇ -aminobutyric acid has a high solubility at 60-100°C, but it is unstable, and it is easily soluble in water, so the best effect is to dissolve ⁇ -aminobutyric acid at 20-35°C.
  • the pH value is controlled at 5.7-7.0, the content of each amino acid is controlled at 80.0-120.0%, the osmolality is not much different, and the amino acid can be stably stored in the solution.
  • solution G which is a compound amino acid injection for livestock liquid.
  • the content of each amino acid will decrease to varying degrees. This is because as the amount of activated carbon increases, the adsorbed amount of amino acids will increase, especially tryptophan and tyrosine.
  • the added amount is 0.05%, the activated carbon has an adsorption effect on amino acids, but after the activated carbon is adsorbed and then sterilized, the solution has good clarity and the sample is stable.
  • 0.05-0.1% activated carbon is added to the preparation process, and the amount of tryptophan and tyrosine raw materials that have a greater impact on the adsorption is appropriately increased during feeding.
  • Step 4) Prepare bottled animal compound amino acid injection:
  • the residual oxygen content in the infusion bottle has been controlled below 3.0% during the entire filling process.
  • the residual oxygen content in the infusion bottle is controlled below 3.0%, which can effectively improve the stability of the amino acids in the injection.
  • Examples 2 to 6 are respectively a preparation method of a compound amino acid injection for animals, which is basically the same as the preparation method in Example 1, except that the amount of each amino acid raw material and the parameters in each step are different. Taking 1000L animal compound injection as an example, the amount of specific active ingredient raw materials is weighed according to the amount of each active ingredient raw material given in Table 1. The specific active ingredient raw materials are shown in Table 1; each of the examples Various process parameters in the steps, the specific parameters are shown in Table 2:
  • the compound amino acid injection for animals prepared by the method in Example 1 was used for quality inspection.
  • the specific detection methods are as follows:
  • the accelerated test is placed for 6 months at a temperature of 40 ⁇ 2°C and a relative humidity of 75 ⁇ 5%, and samples are taken at the end of the 0th, 1st, 2nd, 3rd and 6th months of the test period.
  • the quality standards of "National Food and Drug Administration Drug Standards" WS1 ⁇ (X ⁇ 324) ⁇ 2003Z have been tested, and the specific testing results are shown in Table 4:
  • the preparation method of the present invention can prepare more Stable compound amino acid injection for livestock.
  • Example 7 According to the quality inspection method of Example 7, the animal compound amino acid injection prepared by the preparation method of Examples 1 to 6 and the existing animal compound amino acid injection were placed for 24 months, and the quality test was compared.
  • the specific test The results are as follows:
  • the animal compound amino acid injection prepared by any of the preparation methods of Examples 1 to 6 is applied to test animals, and the specific method is as follows:
  • Bovine viral diarrhea is more susceptible to young cows, and generally exhibits mild symptoms, but sometimes it breaks out suddenly, and the whole group shows severe symptoms.
  • Acute clinical symptoms include sudden fever, body temperature rising to 40-42°C, leukopenia, lack of food or refusal to eat, rumination ceases, rapid breathing and heartbeat, cough, runny nose, oral mucosa flushing, increased saliva, and subsequent erosions and diarrhea Like water, it lasts for several days, with bubbles and blood mixed in the stool. In severe cases, they die of dehydration and exhaustion.
  • the course of the disease is 1 to 3 weeks, and the morbidity and mortality of calves can be greater than 90%.
  • the clinical symptoms of chronic type are not obvious, and the sick cattle show slow growth and development, weight loss, and continuous or intermittent diarrhea. The course of the disease is 2 to 6 months.
  • the compound amino acid injection for livestock has the effects of improving the spirit, increasing appetite, and promoting physical recovery of frail cows after diarrhea, and can be used for adjuvant treatment of frail cows.
  • the compound amino acid injections for livestock prepared in Examples 1 to 6 are better than the existing compound amino acid injections for livestock in recovering frailty after diarrhea in cattle.
  • Dogs of different ages, genders, and breeds can develop canine parvovirus disease throughout the year (mainly puppies, especially puppies before and after weaning are most susceptible).
  • the clinical symptoms of this disease include depression, loss of appetite, severe vomiting, diarrhea, and blood in the stool.
  • the dog will die due to imbalance of water and electrolyte balance, loss of nutrients in the body and acidosis.
  • the morbidity rate is 20-100%, and the mortality rate is 50-100%.
  • fasting and drinking are required. Therefore, the key to rehydration, energy and nutrients is the key to the sick dog. Otherwise, the sick dog is prone to hypoproteinemia and edema. Due to frequent vomiting, oral drugs should not be used.
  • Infusion therapy is the key to treatment. , Timely replenishment of energy, protein and nutrients required by the animal body is the top priority.
  • the Beagle dog of Beijing Amerseys Biotechnology Co., Ltd. has diarrhea symptoms. After the clinical symptoms and the parvovirus test paper, the diagnosis is parvovirus disease.
  • the treatment plan is the plan shown in Table 7 and the 10mg/kg antibiotic sulfate card. Namycin and 1mL of ATP ⁇ 2Na are combined for treatment.
  • the compound amino acid injection for animals can improve the nutritional status of parvovirus-infected dogs, promote the regression of symptoms, and shorten the recovery time. It can be used for the auxiliary treatment of parvovirus-infected dogs.
  • Animal compound amino acid injection can make dogs timely supplement nutrition after illness. After injection, the dog's appetite will be significantly increased, and the weight will be restored. It will help to resolve symptoms such as vomiting and dehydration, and can reduce the mortality of sick dogs.
  • the compound amino acid injections for animals prepared in Examples 1 to 6 have better recovery effects on sick dogs than the existing compound amino acid injections for animals.
  • Embodiments 1 to 6 are only preferred embodiments of the present invention, and are not intended to limit other forms of the present invention. Any person familiar with the profession may use the above technical content as inspiration to make changes or modifications. They are equivalent embodiments with equivalent changes, but simple modifications, equivalent changes and modifications made to the above embodiments without departing from the technical essence of the claims of the present invention still fall within the protection scope of the claims of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A preparation method for a compound amino acid injection for livestock, comprising: boiling water for injection for sterilization, and then adding an antioxidant ethylenediaminetetraacetic acid disodium salt and an antioxidant sodium bisulfite at 75-95°C under the protection of a CO 2 gas flow; adding 15 amino acids at 70-100°C under the protection of CO 2 gas, then adding tryptophan, tyrosine, and cysteine hydrochloride at 60-70°C, finally adding γ-aminobutyric acid at 20-35°C, regulating the pH value, performing decolorization, etc. The problem of poor stability of amino acid injections for livestock is solved. An amino acid injection for livestock is prepared by multi-step feeding; tryptophan, tyrosine, and cysteine hydrochloride are added at 60-70°C under the protection of CO2; thus, the stability of the tryptophan and the tyrosine is effectively improved and the tryptophan and the tyrosine are prevented from being oxidized; the prepared injection is suitable for disease treatment of livestock and body recovery after diseases.

Description

畜用复方氨基酸注射液的制备方法Preparation method of compound amino acid injection for animal use 技术领域Technical field
本发明属于畜牧兽医技术领域,涉及一种畜用注射液的制备方法,具体地说是一种畜用复方氨基酸注射液的制备方法。The invention belongs to the technical field of animal husbandry and veterinary medicine, and relates to a preparation method of animal injection, in particular to a preparation method of animal compound amino acid injection.
背景技术Background technique
目前用于增强动物体能的补充液主要使用葡萄糖注射液、氯化钠注射液和葡萄糖氯化钠注射液。这三种注射液主要起补充水分和能量,以及调节机体电解质的平衡作用,但无法改善动物机体营养状况和补充动物机体所需氨基酸,进而无法有效调节动物采食量,尤其针对是体弱、发病期间的动物,更需要通过补充氨基酸提高营养,进而促进动物的痊愈。At present, the supplementary liquid used to enhance the physical fitness of animals mainly uses glucose injection, sodium chloride injection and glucose sodium chloride injection. These three injections mainly play the role of supplementing water and energy, and regulating the balance of body electrolytes, but they cannot improve the nutritional status of the animal body and supplement the amino acids required by the animal body, and thus cannot effectively regulate the animal's feed intake, especially for the weak During the onset of the disease, the animals need to supplement amino acids to improve their nutrition to promote the recovery of the animals.
一般体弱、发病的动物大多表现出食欲下降、采食量减少、身体虚弱等症状,其体内营养物质由于上述症状随着时间的延长,大量流失。如果上述症状不及时改善,将导致动物生长缓慢甚至死亡,进而为养殖业带来较大的经济损失。In general, frail and diseased animals mostly show symptoms such as decreased appetite, reduced feed intake, and physical weakness. Due to the above symptoms, a large amount of nutrients in their bodies are lost over time. If the above symptoms are not improved in time, the animals will grow slowly or even die, which in turn will bring greater economic losses to the breeding industry.
专利号为201210000911.5的中国发明专利公开了一种复方氨基酸注射液的技术方案,该技术方案主要用于动物疾病治疗及病后恢复期的机体修复,补充动物机体所需的必须氨基酸和非必须氨基酸,辅助治疗疾病和病后恢复期增强体能,增加动物的采食量。The Chinese invention patent with the patent number 201210000911.5 discloses a technical solution of compound amino acid injection. The technical solution is mainly used for the treatment of animal diseases and the restoration of the body during the recovery period after the disease, supplementing the essential and non-essential amino acids required by the animal body. , Adjuvant treatment of diseases and post-ill recovery period to enhance physical fitness and increase animal feed intake.
该技术方案对动物疾病治疗及病后恢复期的机体修复有一定的疗效,虽然该发明专利公开了复方氨基酸注射液的制备方法,但制备的畜用复方氨基酸注射液仍存在稳定性差的缺陷,存在上述缺陷的具体原因如下:This technical solution has a certain effect on the treatment of animal diseases and the restoration of the body in the recovery period after the disease. Although the invention patent discloses the preparation method of compound amino acid injection, the prepared animal compound amino acid injection still has the defect of poor stability. The specific reasons for the above defects are as follows:
现有的畜用复方氨基酸注射液制备过程中是在二氧化碳保护下,将酪氨酸和其他氨基酸一并加入到75~95℃的基础液中。但由于酪氨酸在高温下不稳定,容易氧化变质,进而降低了畜用复方氨基酸注射液的稳定性,不利于畜用复方 氨基酸注射液的制备和储存。In the preparation process of the existing animal compound amino acid injection, under the protection of carbon dioxide, tyrosine and other amino acids are added to the basic liquid at 75-95°C. However, because tyrosine is unstable at high temperatures and is prone to oxidative deterioration, the stability of compound amino acid injections for livestock is reduced, which is not conducive to the preparation and storage of compound amino acid injections for livestock.
综上所述,现有的畜用复方氨基酸注射液中氨基酸稳定性差,不利于畜用复方氨基酸注射液的储存。In summary, the existing animal compound amino acid injections have poor amino acid stability, which is not conducive to the storage of animal compound amino acid injections.
发明内容Summary of the invention
本发明的目的,是要提供一种畜用复方氨基酸注射液的制备方法,以解决畜用注射液中各氨基酸稳定性差的问题。The purpose of the present invention is to provide a method for preparing a compound amino acid injection for livestock, so as to solve the problem of poor stability of each amino acid in the injection for livestock.
为了实现上述目的,本发明采用的技术方案是:In order to achieve the above objective, the technical solution adopted by the present invention is:
一种畜用复方氨基酸注射液的制备方法,包括依次进行的以下步骤:A preparation method of compound amino acid injection for animal use includes the following steps in sequence:
步骤1)制备基础液:Step 1) Prepare the basic solution:
取重量份数600~800份注射用水煮沸杀菌,通入CO 2气体,同时将水温控制在75~100℃,在CO 2气流保护下,加入抗氧剂乙二胺四乙酸二钠和抗氧剂亚硫酸氢钠,溶解,制得基础液A; Take 600-800 parts by weight of water for injection and boil it for sterilization, pass in CO 2 gas, and control the water temperature at 75-100 ℃ at the same time, under the protection of CO 2 gas flow, add the antioxidant disodium edetate and antioxidant Sodium bisulfite, dissolve to prepare basic liquid A;
步骤2)制备中间溶液:Step 2) Prepare the intermediate solution:
在CO 2气体保护下,基础液A中加入B组氨基酸,70~100℃溶解,再自然降温至60~70℃,制得溶液C; Under the protection of CO 2 gas, add group B amino acids to basic solution A, dissolve at 70-100°C, and then naturally cool down to 60-70°C to prepare solution C;
其中,B组氨基酸以重量份数计,包括:1.00~4.00份精氨酸、0.80~2.54份组氨酸、1.50~2.88份亮氨酸、0.50~2.00份异亮氨酸、1.00~4.50份赖氨酸、1.00~2.96份苯丙氨酸、0.80~2.11份苏氨酸、0.50~2.50份缬氨酸、0.50~2.10份甲硫氨酸、1.00~3.45份甘氨酸、0.80~3.00份丙氨酸、0.50~2.40份脯氨酸、0.25~1.50份丝氨酸、0.50~1.25份门冬氨酸、0.80~2.25份谷氨酸;Among them, group B amino acids are calculated in parts by weight, including: 1.00 to 4.00 parts of arginine, 0.80 to 2.54 parts of histidine, 1.50 to 2.88 parts of leucine, 0.50 to 2.00 parts of isoleucine, and 1.00 to 4.50 parts Lysine, 1.00 to 2.96 parts of phenylalanine, 0.80 to 2.11 parts of threonine, 0.50 to 2.50 parts of valine, 0.50 to 2.10 parts of methionine, 1.00 to 3.45 parts of glycine, 0.80 to 3.00 parts of alanine Acid, 0.50 to 2.40 parts of proline, 0.25 to 1.50 parts of serine, 0.50 to 1.25 parts of aspartic acid, 0.80 to 2.25 parts of glutamic acid;
在CO 2气体保护下,溶液C中加入D组氨基酸,60~70℃溶解,自然降温至20~35℃,制得溶液E; Under the protection of CO 2 gas, add group D amino acids to solution C, dissolve at 60~70℃, and naturally cool to 20~35℃ to prepare solution E;
其中,D组氨基酸以重量份数计,包括:0.20~0.70份色氨酸、0.05~0.15份酪氨酸、0.20~1.00份盐酸半胱氨酸;Among them, the amino acids of group D are calculated in parts by weight, including: 0.20 to 0.70 parts of tryptophan, 0.05 to 0.15 parts of tyrosine, and 0.20 to 1.00 parts of cysteine hydrochloride;
在CO 2气体保护下,溶液E中加入0.50~2.00份γ-氨基丁酸,20~35℃溶解后,调节pH值至5.7~7.0,定容至体积份数1000份,得中间溶液F; Under the protection of CO 2 gas, add 0.50 to 2.00 parts of γ-aminobutyric acid to solution E. After dissolving at 20 to 35°C, adjust the pH to 5.7 to 7.0, and dilute to 1000 parts by volume to obtain intermediate solution F;
其中,重量份数与体积份数单位的比为kg:L;Among them, the ratio of parts by weight to parts by volume is kg:L;
步骤3)制备畜用复方氨基酸注射液:Step 3) Preparation of compound amino acid injection for animal use:
在CO 2气体保护下,中间溶液F中加入活性炭,20~35℃脱色,过滤,制得所述畜用复方氨基酸注射液。 Under the protection of CO 2 gas, active carbon is added to the intermediate solution F, decolorized at 20-35° C., and filtered to prepare the compound amino acid injection for livestock.
作为本发明的一种限定,对制得的所述畜用复方氨基酸注射液进行灭菌。As a limitation of the present invention, the prepared animal compound amino acid injection is sterilized.
作为本发明的进一步限定,灭菌前,在CO 2气体保护下,灌装所述畜用复方氨基酸注射液。 As a further limitation of the present invention, before sterilization, under the protection of CO 2 gas, the animal compound amino acid injection is filled.
作为本发明的一种限定,步骤3)中,活性炭与中间溶液F的重量体积比为0.5~1kg:1000L。As a limitation of the present invention, in step 3), the weight-volume ratio of the activated carbon to the intermediate solution F is 0.5-1 kg:1000L.
作为本发明的进一步限定,步骤3)中,脱色的温度为20~35℃、时间为30~40min。As a further limitation of the present invention, in step 3), the decolorization temperature is 20 to 35° C. and the time is 30 to 40 min.
作为本发明的进一步限定,步骤3)中,过滤依次包括粗滤、精滤;As a further limitation of the present invention, in step 3), filtration includes coarse filtration and fine filtration in sequence;
精滤为微孔滤芯过滤;Fine filtration is a microporous filter element filtration;
微孔滤芯的孔径为0.45μm、0.22μm或0.20μm。The pore size of the microporous filter element is 0.45μm, 0.22μm or 0.20μm.
作为本发明的更进一步限定,所述灌装过程中容器内残氧量≤3%。As a further limitation of the present invention, the residual oxygen content in the container during the filling process is less than or equal to 3%.
作为本发明的进一步限定,所述灭菌的温度为110~121℃、时间为15~40min。As a further limitation of the present invention, the sterilization temperature is 110-121°C, and the time is 15-40 min.
本发明与现有技术相比,通过改变工艺参数,提高了畜用复方氨基酸注射液中氨基酸的含量和稳定性,具体如下:Compared with the prior art, the present invention improves the content and stability of amino acids in compound amino acid injections for livestock by changing the process parameters, and the details are as follows:
其一,本发明采用分步加料制备畜用氨基酸注射液,在CO 2保护下于60~70℃同时加入色氨酸、酪氨酸、盐酸半胱氨酸,降低了酪氨酸的加料温度,在保证酪氨酸的溶解度不降低的同时,有效防止色氨酸和酪酸的氧化,提高畜 用复方氨基酸注射液的稳定性; First, the present invention adopts stepwise feeding to prepare animal amino acid injection, and simultaneously adds tryptophan, tyrosine, and cysteine hydrochloride at 60-70°C under the protection of CO 2 to reduce the feeding temperature of tyrosine , While ensuring that the solubility of tyrosine does not decrease, it effectively prevents the oxidation of tryptophan and tyrosine, and improves the stability of compound amino acid injections for livestock;
其二,盐酸半胱氨酸与酪氨酸和色氨酸一起添加,能够保护色氨酸和酪氨酸不被氧化,有效提高色氨酸和酪氨酸的稳定性,且色氨酸在60~70℃时溶解度达到最佳,在提高了畜用氨基酸注射液中色氨酸和酪氨酸的含量的同时,也提高了酪氨酸和色氨酸的稳定性。Second, the addition of cysteine hydrochloride together with tyrosine and tryptophan can protect tryptophan and tyrosine from being oxidized, and effectively improve the stability of tryptophan and tyrosine, and the level of tryptophan is 60%. The solubility reaches the best at ~70℃, which not only increases the content of tryptophan and tyrosine in animal amino acid injection, but also improves the stability of tyrosine and tryptophan.
其三,通过改变加料条件制备畜用氨基酸注射液,缩短了溶解时间,进而减少了制备时间,提高了生产效率。Third, by changing the feeding conditions to prepare animal amino acid injections, the dissolution time is shortened, thereby reducing the preparation time and improving the production efficiency.
本发明制备的畜用复方氨基酸注射液适用于畜牧动物疾病治疗期间及病后恢复期的机体修复。The animal compound amino acid injection prepared by the invention is suitable for body repair during the treatment of animal diseases and during the recovery period after the disease.
具体实施方式Detailed ways
下面通过具体实施例对本发明做进一步详细说明,应当理解所描述的实施例仅用于解释本发明,并不限定本发明。The present invention will be further described in detail below through specific embodiments. It should be understood that the described embodiments are only used to explain the present invention and do not limit the present invention.
实施例1畜用复方氨基酸注射液的制备方法Example 1 Preparation method of compound amino acid injection for livestock
本实施例为畜用复方氨基酸注射液的制备方法,以1m3畜用复方注射液为例,其具体制备方法包括依次进行的以下步骤:This embodiment is a preparation method of compound amino acid injection for animals. Taking 1m3 compound injection for animals as an example, the specific preparation method includes the following steps in sequence:
步骤1)制备基础液:Step 1) Prepare the basic solution:
取1000L注射用水经煮沸杀菌40min,备用;Take 1000L of water for injection and sterilize it by boiling for 40min, then set aside;
称取0.89kg亚硫酸氢钠和0.10kg乙二胺四乙酸二钠,备用;Weigh 0.89kg of sodium bisulfite and 0.10kg of disodium edetate for use;
取600L注射用水置于浓配罐中,通入CO 2气流,同时将水温控制在95℃,在CO 2气流保护下加入0.89kg乙二胺四乙酸二钠和0.10kg亚硫酸氢钠,搅拌使其完全溶解,制得基础液A。 Take 600L of water for injection and place it in a concentrated mixing tank, pass CO 2 gas flow, and at the same time control the water temperature at 95°C, add 0.89kg disodium ethylenediaminetetraacetic acid and 0.10kg sodium bisulfite under the protection of CO 2 gas flow, and stir Make it completely dissolve, and prepare the base liquid A.
其中,亚硫酸氢钠具有防止色氨酸和酪氨酸氧化的作用,因此在加入各氨基酸之前加入亚硫酸氢钠,抗氧化作用更佳,乙二胺四乙酸二钠可以和原料中所带入的金属离子进行螯合作用,避免金属离子催化氧化氨基酸,因此在本实 施例中加入各氨基酸之前先溶解亚硫酸氢钠和乙二胺四乙酸二钠。Among them, sodium bisulfite has the effect of preventing the oxidation of tryptophan and tyrosine. Therefore, adding sodium bisulfite before adding each amino acid has a better antioxidant effect. Disodium ethylenediaminetetraacetate can be combined with the raw materials. The introduced metal ions perform chelation to prevent the metal ions from catalyzing the oxidation of amino acids. Therefore, in this embodiment, the sodium bisulfite and disodium edetate are dissolved before adding each amino acid.
复方氨基酸注射液中色氨酸是属于易于氧化分解的成分,其他氨基酸也存在氧化分解的可能,在生产及储存过程中,氨基酸的稳定性受药液中氧含量影响较大,药液中含氧量越高,氨基酸氧化分解越多,稳定性越差,药液颜色加深,因此在制备开始时就使用惰性气体保护,能够有效降低药液中氧的含量,使得氨基酸在之后的灭菌及储存过程中更加稳定。Tryptophan in compound amino acid injection is a component that is easy to oxidize and decompose. Other amino acids may also be oxidized and decomposed. During production and storage, the stability of amino acids is greatly affected by the oxygen content in the liquid. The higher the oxygen content, the more the amino acid is oxidized and decomposed, the worse the stability, and the darker the color of the drug solution. Therefore, the inert gas protection is used at the beginning of the preparation, which can effectively reduce the oxygen content in the drug solution, so that the amino acid can be sterilized and sterilized later. More stable during storage.
步骤2)制备中间溶液:Step 2) Prepare the intermediate solution:
称取1.00kg精氨酸、2.54kg组氨酸、2.54kg亮氨酸、1.52kg异亮氨酸、3.33kg赖氨酸、2.96kg苯丙氨酸、0.80kg苏氨酸、2.50kg缬氨酸、1.79kg甲硫氨酸、3.24kg甘氨酸、0.80kg丙氨酸、2.40kg脯氨酸、0.25kg丝氨酸、0.50kg门冬氨酸、1.34kg谷氨酸,统称为B组氨基酸;Weigh 1.00kg arginine, 2.54kg histidine, 2.54kg leucine, 1.52kg isoleucine, 3.33kg lysine, 2.96kg phenylalanine, 0.80kg threonine, 2.50kg valine Acid, 1.79kg methionine, 3.24kg glycine, 0.80kg alanine, 2.40kg proline, 0.25kg serine, 0.50kg aspartic acid, 1.34kg glutamic acid, collectively referred to as group B amino acids;
在CO 2气流保护下,将称量好的B组氨基酸加至温度为100℃的基础液A中,搅拌溶解,制得溶液C,溶液C自然降温至70℃; Under the protection of CO 2 airflow, add the weighed group B amino acids to the basic liquid A at a temperature of 100 ℃, stir to dissolve to obtain solution C, and the temperature of solution C is naturally cooled to 70 ℃;
称取0.32kg色氨酸、0.15kg酪氨酸、0.76kg盐酸半胱氨酸,统称为D组氨基酸Weigh 0.32kg tryptophan, 0.15kg tyrosine, 0.76kg cysteine hydrochloride, collectively referred to as group D amino acids
在CO 2气流保护下,将D组氨基酸加入到温度为70℃的溶液C中,搅拌溶解,制得溶液E,溶液E自然降温至30℃; Under the protection of CO 2 gas flow, add group D amino acids to solution C at a temperature of 70°C, stir to dissolve to obtain solution E, and solution E is naturally cooled to 30°C;
在CO 2气流保护下,将0.89kgγ-氨基丁酸加入到温度为30℃的溶液E中,搅拌溶解,加入注射用水至近1000L,再用质量浓度为20%氢氧化钠溶液调节pH值至6.0,最终定容至1000L,制得中间溶液F。 Under the protection of CO 2 gas flow, add 0.89kg of γ-aminobutyric acid to solution E at a temperature of 30℃, stir to dissolve, add water for injection to nearly 1000L, and then adjust the pH value to 6.0 with a mass concentration of 20% sodium hydroxide solution , The final volume was adjusted to 1000L, and the intermediate solution F was prepared.
氨基酸的溶解时间随温度的升高而缩短,温度为100℃时,溶解时间最短,而高于70℃时的各温度条件下,大部分氨基酸含量变化不再发生明显变化。The dissolution time of amino acids decreases with the increase of temperature. When the temperature is 100℃, the dissolution time is the shortest, and when the temperature is higher than 70℃, most of the amino acid content changes no longer change significantly.
但由于酪氨酸、色氨酸不稳定,随着温度升高,含量反而大幅度下降,酪氨酸、色氨酸在60~70℃的溶液内溶解含量较高(其中色氨酸含量相对于100℃ 时提高了7.4~9.0%,酪氨酸含量也有所提高)。综合考虑含量与溶解时间等因素,分步加入各氨基酸,将精氨酸、组氨酸、亮氨酸、异亮氨酸、赖氨酸、苯丙氨酸、苏氨酸、缬氨酸、甲硫氨酸、甘氨酸、丙氨酸、脯氨酸、丝氨酸、门冬氨酸、谷氨酸于70~100℃之间溶解,将色氨酸和酪氨酸于60~70℃时溶解,并同时溶解盐酸半胱氨酸,以降低色氨酸和酪氨酸溶解过程中的氧化作用。However, due to the instability of tyrosine and tryptophan, the content of tyrosine and tryptophan decreases drastically as the temperature rises. The soluble content of tyrosine and tryptophan in the solution at 60~70℃ is relatively high (the content of tryptophan is relatively high). At 100°C, it increased by 7.4 to 9.0%, and the tyrosine content also increased). Considering factors such as content and dissolution time, each amino acid is added step by step, adding arginine, histidine, leucine, isoleucine, lysine, phenylalanine, threonine, valine, Methionine, glycine, alanine, proline, serine, aspartic acid, and glutamic acid are dissolved at 70~100℃, tryptophan and tyrosine are dissolved at 60~70℃, At the same time, it dissolves cysteine hydrochloride to reduce the oxidation of tryptophan and tyrosine in the process of dissolving.
由于γ-氨基丁酸在60~100℃时溶解度较高,但是不稳定,且其易溶于水,因此,将γ-氨基丁酸在20~35℃时溶解,效果最佳。Because γ-aminobutyric acid has a high solubility at 60-100°C, but it is unstable, and it is easily soluble in water, so the best effect is to dissolve γ-aminobutyric acid at 20-35°C.
在制备复方氨基酸注射液过程中,将pH值控制在5.7~7.0,各氨基酸含量控制在80.0~120.0%之间,渗透压摩尔浓度差别不大,氨基酸在溶液中能够稳定储存。During the preparation of the compound amino acid injection, the pH value is controlled at 5.7-7.0, the content of each amino acid is controlled at 80.0-120.0%, the osmolality is not much different, and the amino acid can be stably stored in the solution.
步骤3)制备畜用复方氨基酸注射液:Step 3) Preparation of compound amino acid injection for animal use:
在CO 2气体保护下,将1kg活性炭加至温度为30℃的中间溶液F中,脱色30min,经粗滤、0.45μm的微孔滤芯精滤,制得溶液G,即为畜用复方氨基酸注射液。 Under the protection of CO 2 gas, add 1 kg of activated carbon to the intermediate solution F at a temperature of 30 ℃, decolorize for 30 minutes, filter through coarse filtration and fine filtration with a 0.45 μm microporous filter element to obtain solution G, which is a compound amino acid injection for livestock liquid.
加入0.05~0.1%的活性炭脱色,各氨基酸含量均有不同程度的降低,这是由于随着活性炭加入量的增加,氨基酸的被吸附量也会增加,尤其是色氨酸和酪氨酸。加入量为0.05%时,活性炭对氨基酸有吸附作用,但经活性炭吸附后再经灭菌,溶液澄明度良好,样品稳定。为提高产品质量,在制备工艺中加入0.05~0.1%的活性炭,并在投料时对吸附适当增加对其影响较大的色氨酸和酪氨酸原料投料量。Adding 0.05-0.1% activated carbon to decolorize, the content of each amino acid will decrease to varying degrees. This is because as the amount of activated carbon increases, the adsorbed amount of amino acids will increase, especially tryptophan and tyrosine. When the added amount is 0.05%, the activated carbon has an adsorption effect on amino acids, but after the activated carbon is adsorbed and then sterilized, the solution has good clarity and the sample is stable. In order to improve product quality, 0.05-0.1% activated carbon is added to the preparation process, and the amount of tryptophan and tyrosine raw materials that have a greater impact on the adsorption is appropriately increased during feeding.
步骤4)制备瓶装的畜用复方氨基酸注射液:Step 4) Prepare bottled animal compound amino acid injection:
在CO 2气体保护下,将溶液G灌装至1000mL输液瓶中,115℃灭菌30min,灯检合格,制得瓶装的畜用复方氨基酸注射液; Under the protection of CO 2 gas, fill solution G into a 1000 mL infusion bottle, sterilize at 115°C for 30 minutes, and pass the lamp inspection to prepare a bottled animal compound amino acid injection;
整个灌装过程中输液瓶内残氧量一直控制在3.0%以下。The residual oxygen content in the infusion bottle has been controlled below 3.0% during the entire filling process.
在灌装过程中将输液瓶内残氧量控制在3.0%以下,能够有效提高注射液中各氨基酸的稳定性。During the filling process, the residual oxygen content in the infusion bottle is controlled below 3.0%, which can effectively improve the stability of the amino acids in the injection.
实施例2~6畜用复方氨基酸注射液的制备方法Example 2-6 Preparation method of compound amino acid injection for animal use
实施例2~6分别为一种畜用复方氨基酸注射液的制备方法,与实施例1中的制备方法基本相同,不同之处在于各氨基酸原料的用量,以及各步骤中的参数有区别。以1000L畜用复方注射液为例,制成其具体有效成分原料的用量分别按照表1中给出的各有效成分原料的用量称量,具体有效成分原料见表1;各实施例中的各步骤中各项工艺参数,具体参数见表2:Examples 2 to 6 are respectively a preparation method of a compound amino acid injection for animals, which is basically the same as the preparation method in Example 1, except that the amount of each amino acid raw material and the parameters in each step are different. Taking 1000L animal compound injection as an example, the amount of specific active ingredient raw materials is weighed according to the amount of each active ingredient raw material given in Table 1. The specific active ingredient raw materials are shown in Table 1; each of the examples Various process parameters in the steps, the specific parameters are shown in Table 2:
表1各有效成分原料的用量一览表Table 1 List of the dosage of each active ingredient raw material
Figure PCTCN2020109808-appb-000001
Figure PCTCN2020109808-appb-000001
Figure PCTCN2020109808-appb-000002
Figure PCTCN2020109808-appb-000002
表2实施例2~6的各项工艺参数一览表Table 2 List of various process parameters of Examples 2 to 6
Figure PCTCN2020109808-appb-000003
Figure PCTCN2020109808-appb-000003
实施例1~6制备的畜用复方氨基酸注射液中各氨基酸含量与现有畜用复方氨基酸注射液中各氨基酸含量的具体情况见表3:The specific conditions of the content of each amino acid in the compound amino acid injection for livestock prepared in Examples 1 to 6 and the content of each amino acid in the existing compound amino acid injection for livestock are shown in Table 3:
表3实施例1~6中制得的畜用复方氨基酸注射液质量检测结果一览表Table 3 List of quality test results of compound amino acid injections for livestock prepared in Examples 1 to 6
Figure PCTCN2020109808-appb-000004
Figure PCTCN2020109808-appb-000004
Figure PCTCN2020109808-appb-000005
Figure PCTCN2020109808-appb-000005
Figure PCTCN2020109808-appb-000006
Figure PCTCN2020109808-appb-000006
由表3可知,实施例1~6制备的畜用复方氨基酸注射液的颜色相对于现有畜用复方氨基酸注射液由微黄色变成无色透明,且相对于现有的畜用复方氨基酸注射液均有所提高,且其他检查相关项均已全部合格。It can be seen from Table 3 that the color of the compound amino acid injections for animals prepared in Examples 1 to 6 has changed from slightly yellow to colorless and transparent compared with the existing compound amino acid injections for animals, and compared with the existing compound amino acid injections for animals. The liquid has been improved, and other inspection related items have all been qualified.
实施例7畜用复方氨基酸注射液的质量检测Example 7 Quality Inspection of Compound Amino Acid Injection for Animals
本实施例利用实施例1中的方法所制得的畜用复方氨基酸注射液,进行了质量检测。具体检测方法如下:In this example, the compound amino acid injection for animals prepared by the method in Example 1 was used for quality inspection. The specific detection methods are as follows:
加速试验在温度40±2℃、相对湿度75±5%的条件下放置6个月,在试验期间第0个月、1个月、2个月、3个月、6个月末分别取样,按《国家食品药品监督管理局药品标准》WS1~(X~324)~2003Z的质量标准进行了检测,具体检测结果见表4:The accelerated test is placed for 6 months at a temperature of 40±2℃ and a relative humidity of 75±5%, and samples are taken at the end of the 0th, 1st, 2nd, 3rd and 6th months of the test period. The quality standards of "National Food and Drug Administration Drug Standards" WS1~(X~324)~2003Z have been tested, and the specific testing results are shown in Table 4:
表4畜用复方氨基酸注射液质量检测结果Table 4 Quality test results of compound amino acid injection for livestock
Figure PCTCN2020109808-appb-000007
Figure PCTCN2020109808-appb-000007
Figure PCTCN2020109808-appb-000008
Figure PCTCN2020109808-appb-000008
由表4可知,实施例1制备的畜用复方氨基酸注射液经过加速试验,各指标无明显变化,样品质量稳定性良好,具有很好的稳定性,因此,本发明的制备方法能够制备出更加稳定的畜用复方氨基酸注射液。It can be seen from Table 4 that the animal compound amino acid injection prepared in Example 1 has undergone an accelerated test, with no significant changes in various indicators, and the sample has good quality stability and good stability. Therefore, the preparation method of the present invention can prepare more Stable compound amino acid injection for livestock.
实施例8畜用复方氨基酸注射液的稳定性对比Example 8 Comparison of stability of compound amino acid injection for livestock
分别按照实施例7的质量检测方法,利用实施例1~6的制备方法制得的畜用复方氨基酸注射液和现有畜用复方氨基酸注射液放置24个月后分别进行质量检测对比,具体检测结果如下:According to the quality inspection method of Example 7, the animal compound amino acid injection prepared by the preparation method of Examples 1 to 6 and the existing animal compound amino acid injection were placed for 24 months, and the quality test was compared. The specific test The results are as follows:
表5畜用复方氨基酸注射液质量检测对比结果Table 5 Comparison results of quality test of compound amino acid injection for livestock
Figure PCTCN2020109808-appb-000009
Figure PCTCN2020109808-appb-000009
Figure PCTCN2020109808-appb-000010
Figure PCTCN2020109808-appb-000010
由表5可知,现有的畜用复方氨基酸注射液放置24个月后,色氨酸、脯氨酸、γ-氨基丁酸、酪氨酸的含量均有所下降,而本发明制备的畜用复方氨基酸注射液则更加稳定,含量变化不大。实施例1~6制得的畜用复方氨基酸注射液中的各氨基酸含量均高于现有的畜用复方氨基酸注射液,其在24个月内稳定,质量可控,安全可靠。It can be seen from Table 5 that the contents of tryptophan, proline, γ-aminobutyric acid, and tyrosine all decreased after the existing compound amino acid injections for livestock were placed for 24 months. Compound amino acid injection is more stable, and the content does not change much. The content of each amino acid in the animal compound amino acid injection prepared in Examples 1 to 6 is higher than the existing animal compound amino acid injection, which is stable within 24 months, has controllable quality, and is safe and reliable.
实施例9畜用复方氨基酸注射液的应用Example 9 Application of Compound Amino Acid Injection for Animals
本实施例将实施例1~6中任一制备方法所制得的畜用复方氨基酸注射液应用于试验动物,具体方式如下:In this example, the animal compound amino acid injection prepared by any of the preparation methods of Examples 1 to 6 is applied to test animals, and the specific method is as follows:
a1)治疗牛病毒性腹泻上的应用a1) Application in the treatment of bovine viral diarrhea
牛病毒性腹泻病,幼龄牛较易感,一般表现轻度症状,但有时突然暴发,全群表现严重症状。急性型临床症状表现为突然发热,体温升高至40~42℃,白细胞减少,少食或拒食,反刍停止,呼吸、心跳加快,咳嗽、流鼻涕,口腔黏膜潮红,唾液增多,继而出现糜烂,腹泻如水,持续数天,粪便中混有气泡和血液。严重者因脱水和衰竭而死。病程1~3周,犊牛发病死亡率可大于90%。 慢性型临床症状不明显,病牛呈现生长发育缓慢,消瘦,持续或间歇性腹泻病程2~6个月。Bovine viral diarrhea is more susceptible to young cows, and generally exhibits mild symptoms, but sometimes it breaks out suddenly, and the whole group shows severe symptoms. Acute clinical symptoms include sudden fever, body temperature rising to 40-42°C, leukopenia, lack of food or refusal to eat, rumination ceases, rapid breathing and heartbeat, cough, runny nose, oral mucosa flushing, increased saliva, and subsequent erosions and diarrhea Like water, it lasts for several days, with bubbles and blood mixed in the stool. In severe cases, they die of dehydration and exhaustion. The course of the disease is 1 to 3 weeks, and the morbidity and mortality of calves can be greater than 90%. The clinical symptoms of chronic type are not obvious, and the sick cattle show slow growth and development, weight loss, and continuous or intermittent diarrhea. The course of the disease is 2 to 6 months.
采用实施例1~6中任一制备方法所制得的畜用复方氨基酸注射液,进行临床试验:The compound amino acid injection for animal use prepared by any of the preparation methods in Examples 1 to 6 was used for clinical trials:
莱西市众合兴牧的荷斯坦牛,存在腹泻症状,经当地兽医确诊,是由于感染牛病毒引起的,遂采用表6所示的方案配合盐酸林可霉素(使用量为3g/头)进行治疗。Holstein cattle in Zhonghe Xingmu of Laixi City had symptoms of diarrhea. It was confirmed by the local veterinarian that it was caused by infection with a bovine virus. The plan shown in Table 6 was combined with lincomycin hydrochloride (use amount is 3g/head). ) For treatment.
表6畜用复方氨基酸注射液在牛病毒性腹泻上的应用Table 6 Application of Compound Amino Acid Injection for Animals in Bovine Viral Diarrhea
Figure PCTCN2020109808-appb-000011
Figure PCTCN2020109808-appb-000011
由表6可知,畜用复方氨基酸注射液对牛腹泻后体弱奶牛具有改善精神、增加食欲、促进体能恢复作用,可用于体弱牛的辅助治疗。而实施例1~6中制备的畜用复方氨基酸注射液对牛腹泻后体弱恢复的作用优于现有的畜用复方氨基酸注射液。It can be seen from Table 6 that the compound amino acid injection for livestock has the effects of improving the spirit, increasing appetite, and promoting physical recovery of frail cows after diarrhea, and can be used for adjuvant treatment of frail cows. However, the compound amino acid injections for livestock prepared in Examples 1 to 6 are better than the existing compound amino acid injections for livestock in recovering frailty after diarrhea in cattle.
a2)治疗犬细小病毒上的应用a2) Application in the treatment of canine parvovirus
不同年龄、性别、品种的犬一年四季均可发生犬细小病毒病(主要是幼犬,特别是断奶前后的幼犬最易感)。本病的临床症状为患犬精神沉郁,食欲废绝,剧烈呕吐,腹泻,便血,严重者会因水、电解质平衡失调,体内营养物质大量流失并发酸中毒而死亡。发病率为20~100%,死亡率为50~100%。病犬发病期间需禁食禁饮,因此对病犬的补液、能量和营养物质是关键,否则病犬易产生低蛋白血症而出现水肿,由于频繁呕吐,不宜使用口服药物,采用输液疗法是治疗的关键,及时补充动物机体所需能量、蛋白和营养物质是重中之重。Dogs of different ages, genders, and breeds can develop canine parvovirus disease throughout the year (mainly puppies, especially puppies before and after weaning are most susceptible). The clinical symptoms of this disease include depression, loss of appetite, severe vomiting, diarrhea, and blood in the stool. In severe cases, the dog will die due to imbalance of water and electrolyte balance, loss of nutrients in the body and acidosis. The morbidity rate is 20-100%, and the mortality rate is 50-100%. During the onset of the sick dog, fasting and drinking are required. Therefore, the key to rehydration, energy and nutrients is the key to the sick dog. Otherwise, the sick dog is prone to hypoproteinemia and edema. Due to frequent vomiting, oral drugs should not be used. Infusion therapy is the key to treatment. , Timely replenishment of energy, protein and nutrients required by the animal body is the top priority.
采用实施例1~6中任一制备方法所制得的畜用复方氨基酸注射液,进行临床试验:The compound amino acid injection for animal use prepared by any of the preparation methods in Examples 1 to 6 was used for clinical trials:
北京安默赛斯生物科技有限公司的比格犬,存在腹泻症状,经临床症状结合细小病毒试纸检测,诊断为细小病毒病,其治疗方案是表7所示的方案与10mg/kg抗菌素硫酸卡那霉素和1mL的ATP~2Na配合治疗。The Beagle dog of Beijing Amerseys Biotechnology Co., Ltd. has diarrhea symptoms. After the clinical symptoms and the parvovirus test paper, the diagnosis is parvovirus disease. The treatment plan is the plan shown in Table 7 and the 10mg/kg antibiotic sulfate card. Namycin and 1mL of ATP~2Na are combined for treatment.
表7畜用复方氨基酸注射液在犬细小病毒上的应用Table 7 Application of Compound Amino Acid Injection for Animals on Canine Parvovirus
Figure PCTCN2020109808-appb-000012
Figure PCTCN2020109808-appb-000012
Figure PCTCN2020109808-appb-000013
Figure PCTCN2020109808-appb-000013
由表7可知,畜用复方氨基酸注射液对细小病毒感染犬具有改善营养状况、促进症状消退、缩短康复时间的作用,可用于细小病毒感染犬的辅助治疗。畜用复方氨基酸注射液能够使犬病后及时补充营养,注射后,犬只食欲明显增加,体重恢复增长,有助于呕吐、脱水等症状的消退,且能够降低病犬的死亡率。而实施例1~6中制备的畜用复方氨基酸注射液对病犬恢复的作用优于现有的畜用复方氨基酸注射液。It can be seen from Table 7 that the compound amino acid injection for animals can improve the nutritional status of parvovirus-infected dogs, promote the regression of symptoms, and shorten the recovery time. It can be used for the auxiliary treatment of parvovirus-infected dogs. Animal compound amino acid injection can make dogs timely supplement nutrition after illness. After injection, the dog's appetite will be significantly increased, and the weight will be restored. It will help to resolve symptoms such as vomiting and dehydration, and can reduce the mortality of sick dogs. However, the compound amino acid injections for animals prepared in Examples 1 to 6 have better recovery effects on sick dogs than the existing compound amino acid injections for animals.
需要注意,实施例1~6,仅是本发明的较佳实施例,并非是对本发明所作的其他形式的限定,任何熟悉本专业的技术人员都可能利用上述技术内容作为启示加以变更或改型为等同变化的等效实施例,但凡是未脱离本发明权利要求的技术实质,对以上实施例所作出的简单修改、等同变化与改型,仍属于本发明权利要求保护的范围。It should be noted that Embodiments 1 to 6 are only preferred embodiments of the present invention, and are not intended to limit other forms of the present invention. Any person familiar with the profession may use the above technical content as inspiration to make changes or modifications. They are equivalent embodiments with equivalent changes, but simple modifications, equivalent changes and modifications made to the above embodiments without departing from the technical essence of the claims of the present invention still fall within the protection scope of the claims of the present invention.

Claims (8)

  1. 一种畜用复方氨基酸注射液的制备方法,其特征在于,该制备方法包括依次进行的以下步骤:A preparation method of compound amino acid injection for animals, characterized in that the preparation method comprises the following steps in sequence:
    步骤1)制备基础液:Step 1) Prepare the basic solution:
    取注射用水煮沸杀菌,通入CO 2气体,同时将水温控制在75~100℃,在CO 2气流保护下,加入抗氧剂乙二胺四乙酸二钠和抗氧剂亚硫酸氢钠,溶解,制得基础液A; Take the water for injection and boil it for sterilization, pass in CO 2 gas, and control the water temperature at 75-100 ℃ at the same time, under the protection of CO 2 gas flow, add the antioxidant disodium edetate and the antioxidant sodium bisulfite to dissolve , Prepare the basic liquid A;
    步骤2)制备中间溶液:Step 2) Prepare the intermediate solution:
    在CO 2气体保护下,基础液A中加入B组氨基酸,70~100℃溶解,再降温至60~70℃,制得溶液C; Under the protection of CO 2 gas, add group B amino acids to basic solution A, dissolve at 70-100°C, and then lower the temperature to 60-70°C to prepare solution C;
    其中,B组氨基酸包括精氨酸、组氨酸、亮氨酸、异亮氨酸、赖氨酸、苯丙氨酸、苏氨酸、缬氨酸、甲硫氨酸、甘氨酸、丙氨酸、脯氨酸、丝氨酸、门冬氨酸和谷氨酸;Among them, group B amino acids include arginine, histidine, leucine, isoleucine, lysine, phenylalanine, threonine, valine, methionine, glycine, alanine , Proline, serine, aspartic acid and glutamic acid;
    在CO 2气体保护下,溶液C中加入D组氨基酸,60~70℃溶解,降温至20~35℃,制得溶液E; Under the protection of CO 2 gas, add group D amino acids to solution C, dissolve at 60~70℃, and lower the temperature to 20~35℃ to prepare solution E;
    其中,D组氨基酸包括色氨酸、酪氨酸和盐酸半胱氨酸;Among them, group D amino acids include tryptophan, tyrosine and cysteine hydrochloride;
    在CO 2气体保护下,溶液E中加入γ-氨基丁酸,20~35℃溶解后,调节pH值至5.7~7.0,定容,得中间溶液F; Under the protection of CO 2 gas, add γ-aminobutyric acid to solution E, and after dissolving at 20~35℃, adjust the pH value to 5.7~7.0 and constant volume to obtain intermediate solution F;
    步骤3)制备畜用复方氨基酸注射液:Step 3) Preparation of compound amino acid injection for animal use:
    在CO 2气体保护下,中间溶液F加入活性炭,脱色,过滤,制得所述畜用复方氨基酸注射液。 Under the protection of CO 2 gas, the intermediate solution F is added with activated carbon, decolorized and filtered to prepare the animal compound amino acid injection.
  2. 根据权利要求1所述的畜用复方氨基酸注射液的制备方法,其特征在于,对制得的所述畜用复方氨基酸注射液进行灭菌。The method for preparing animal compound amino acid injection according to claim 1, wherein the prepared animal compound amino acid injection is sterilized.
  3. 根据权利要求2所述的畜用复方氨基酸注射液的制备方法,其特征在于,灭菌前,在CO 2气体保护下,灌装所述畜用复方氨基酸注射液。 The method for preparing animal compound amino acid injection according to claim 2, characterized in that, before sterilization, the animal compound amino acid injection is filled under the protection of CO 2 gas.
  4. 权利要求1-3中任一项所述的畜用复方氨基酸注射液的一种制备方法,其特征在于,步骤3)中,活性炭与中间溶液F的重量体积比为0.5~1kg:1000L。A method for preparing animal compound amino acid injection according to any one of claims 1 to 3, characterized in that, in step 3), the weight-volume ratio of activated carbon to intermediate solution F is 0.5-1 kg:1000L.
  5. 根据权利要求4所述的畜用复方氨基酸注射液的制备方法,其特征在于,步骤3)中,脱色的温度为20~35℃、时间为30~40min。The method for preparing animal compound amino acid injection according to claim 4, characterized in that, in step 3), the decolorization temperature is 20-35°C and the time is 30-40 min.
  6. 根据权利要求4所述的畜用复方氨基酸注射液的制备方法,其特征在于,步骤3)中,过滤依次包括粗滤、精滤。The method for preparing animal compound amino acid injection according to claim 4, wherein in step 3), the filtration includes coarse filtration and fine filtration in sequence.
  7. 根据权利要求3所述的畜用复方氨基酸注射液的制备方法,其特征在于,所述灌装过程中容器内残氧量≤3%。The method for preparing animal compound amino acid injection according to claim 3, wherein the residual oxygen content in the container during the filling process is ≤3%.
  8. 根据权利要求2或3所述的畜用复方氨基酸注射液的制备方法,其特征在于,所述灭菌的温度为110~121℃、时间为15~40min。The method for preparing animal compound amino acid injection according to claim 2 or 3, wherein the sterilization temperature is 110-121°C and the time is 15-40 min.
PCT/CN2020/109808 2020-04-08 2020-08-18 Preparation method for compound amino acid injection for livestock WO2021203606A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010269131.5A CN111329836B (en) 2020-04-08 2020-04-08 Preparation method of compound amino acid injection for livestock
CN202010269131.5 2020-04-08

Publications (1)

Publication Number Publication Date
WO2021203606A1 true WO2021203606A1 (en) 2021-10-14

Family

ID=71175447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/109808 WO2021203606A1 (en) 2020-04-08 2020-08-18 Preparation method for compound amino acid injection for livestock

Country Status (2)

Country Link
CN (1) CN111329836B (en)
WO (1) WO2021203606A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111329836B (en) * 2020-04-08 2021-04-30 河北科星药业有限公司 Preparation method of compound amino acid injection for livestock
CN111358753A (en) * 2020-04-08 2020-07-03 河北科星药业有限公司 Compound amino acid injection for livestock and preparation method thereof
CN112190543A (en) * 2020-08-11 2021-01-08 河北科星药业有限公司 Compound amino acid oral solution for dogs and preparation method thereof
CN114601846A (en) * 2020-12-03 2022-06-10 河北科星药业有限公司 Complex vitamin amino acid injection for livestock and preparation method and application thereof
CN115266963B (en) * 2022-06-01 2024-01-05 北京诺康达医药科技股份有限公司 Method for detecting cysteine and cystine in compound amino acid injection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1667887B1 (en) * 1968-02-09 1971-10-07 Knauff Hans Georg Prof Dr Aminosaeurelösungen for parenteral infusion
US20040192751A1 (en) * 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
CN102552250A (en) * 2012-01-04 2012-07-11 河北科星药业有限公司 Compound amino acid injection for livestock as well as preparation method and applications thereof
CN102697775A (en) * 2012-06-15 2012-10-03 福建天泉药业股份有限公司 Compound amino acid drug composition
CN104055766A (en) * 2014-05-21 2014-09-24 刘力 Pharmaceutical composition of compound amino acid injection 18AA and application thereof
CN106361749A (en) * 2016-10-24 2017-02-01 安徽富邦药业有限公司 Preparation method of compound amino acid injection 18AA
CN110507604A (en) * 2019-08-08 2019-11-29 武汉久安药业有限公司 A kind of Amino Acid Compound Injection and preparation method thereof
CN111329836A (en) * 2020-04-08 2020-06-26 河北科星药业有限公司 Preparation method of compound amino acid injection for livestock
CN111358753A (en) * 2020-04-08 2020-07-03 河北科星药业有限公司 Compound amino acid injection for livestock and preparation method thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1667887B1 (en) * 1968-02-09 1971-10-07 Knauff Hans Georg Prof Dr Aminosaeurelösungen for parenteral infusion
US20040192751A1 (en) * 2001-03-15 2004-09-30 Takeshi Abe Amino acid composition for ameliorating liver failure
CN102552250A (en) * 2012-01-04 2012-07-11 河北科星药业有限公司 Compound amino acid injection for livestock as well as preparation method and applications thereof
CN102697775A (en) * 2012-06-15 2012-10-03 福建天泉药业股份有限公司 Compound amino acid drug composition
CN104055766A (en) * 2014-05-21 2014-09-24 刘力 Pharmaceutical composition of compound amino acid injection 18AA and application thereof
CN106361749A (en) * 2016-10-24 2017-02-01 安徽富邦药业有限公司 Preparation method of compound amino acid injection 18AA
CN110507604A (en) * 2019-08-08 2019-11-29 武汉久安药业有限公司 A kind of Amino Acid Compound Injection and preparation method thereof
CN111329836A (en) * 2020-04-08 2020-06-26 河北科星药业有限公司 Preparation method of compound amino acid injection for livestock
CN111358753A (en) * 2020-04-08 2020-07-03 河北科星药业有限公司 Compound amino acid injection for livestock and preparation method thereof

Also Published As

Publication number Publication date
CN111329836A (en) 2020-06-26
CN111329836B (en) 2021-04-30

Similar Documents

Publication Publication Date Title
WO2021203606A1 (en) Preparation method for compound amino acid injection for livestock
WO2021203605A1 (en) Compound amino acid injection for livestock and preparation method therefor
WO2021203607A1 (en) Method for preparing compound amino acid injection for livestock
CA2931109C (en) Composition useful for promoting female fertility
CN102091028A (en) Edaravone injection and preparation method thereof
CN102552250B (en) Compound amino acid injection for livestock as well as preparation method and applications thereof
Breck et al. Dietary histidine affects lens protein turnover and synthesis of N‐acetylhistidine in Atlantic salmon (Salmo salar L.) undergoing parr–smolt transformation
CN103690561B (en) Preparation method of oral liquid
JPH0670718A (en) Nutrient composition
CN1830438A (en) Preparation method of vitamin C freeze dried powder injection
RU2400251C1 (en) Method of treating chronic kidney disease in predialytic and dialytic periods and medication for its realisation
RU2549496C1 (en) Homeopathic medicinal product having stress-protective and growth-stimulating effect, regulating metabolism in young farm animals and poultry
CN114514956A (en) Gel hollow candy for assisting in feeding pet medicaments, and preparation method and application thereof
WO2022047840A1 (en) Compound amino acid solution for animal, preparation method therefor, and application thereof
CN106943428B (en) Amino acid peritoneal dialysis solution for dogs and cats and preparation method thereof
WO2008089776A1 (en) Formulation of and method for producing an infusion rehydration solution
CN115887370A (en) Preparation method of antioxidant-free compound amino acid injection 18AA-II
CN115919896B (en) Trace element composition, preparation method and application thereof
CN114469941A (en) Compound amino acid injection for preventing and treating livestock diseases as well as preparation method and application thereof
RU2783527C1 (en) Method for energy immuno-metabolic correction, increase of resistance and stress resistance of sports horses in the prize period
CN102499930A (en) Medicinal fructose composition and preparation method thereof
CN114601846A (en) Complex vitamin amino acid injection for livestock and preparation method and application thereof
CN101002930B (en) Medicine composition containing aniracetam and brain protein hydrolyte
CN115770217A (en) Preparation method of antioxidant-free compound amino acid injection 18AA
CN116251058A (en) Preparation method of compound amino acid composition without antioxidant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20930396

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20930396

Country of ref document: EP

Kind code of ref document: A1